The study is a Phase 2a, randomized, double-blind, placebo-controlled, sequential cohort study to evaluate the pharmacodynamics (PD), safety and pharmacokinetics (PK) of multiple doses of SRSD107 in participants with coronary arterial disease (CAD) and/or peripheral arterial disease (PAD) with aspirin as background concomitant therapy.

Inclusion Criteria:

• Able to comprehend and willing to sign an ICF and to abide by the study restrictions.
• Males or females aged 18 to 75 years, inclusive.
• Body mass index (BMI) between 18.0 and 35.0 kg/m2, inclusive.
• History of chronic coronary and/or peripheral arterial disease

Exclusion Criteria:

• Known bleeding disorder
• Severe heart failure with known left ventricular ejection fraction <35%, or New York Heart Association (NYHA) class III or IV symptoms.
• Genetic cardiomyopathies or other non-ischemic cardiomyopathies that are not related to atherosclerotic cardiovascular disease.
• History of ethanol abuse or addictive drug use (cannabis products allowed) within 6 months of screening.
• Receipt of an investigational drug (IP) within 30 days or 5 half-lives of that drug, whichever is longer, prior to dose administration in this study.
• Previous use of SRSD107.